Digital Exposure Verification

Every clinical trial starts with the same assumption: the medication was taken. Massyst introduces a new vision for verifying when treatment was actually delivered and received.

Better adherence data Move from estimates to verified exposure signals.

Better evidence Understand treatment outcomes with cleaner inputs.

Better decisions Support sponsors, CROs and research teams with actionable insight.

Request the Executive Discussion Paper

Explore the concept of Digital Exposure Verification (DEV) and the future of adherence intelligence in clinical research.

Email request Send your request to info@massyst.com

Suggested subject Request for Executive Discussion Paper – DEV

Request your copy

What happens next?
After you have received and reviewed the paper, Massyst may contact selected respondents for a follow-up discussion. These conversations are intended to explore different perspectives, opportunities, challenges and future applications of Digital Exposure Verification.

Why now

Clinical research measures outcomes exceptionally well. Exposure is still often assumed.

In many trials, adherence is reconstructed through self-reporting, diaries, pill counts or delayed data. These methods are useful, but they do not always provide a precise view of actual medication exposure. Digital Exposure Verification adds a new layer: a verified signal of whether and when medication was made available to the participant.

From adherence monitoring

Pico and PicoCare already support medication intake routines and capture missed, delayed and confirmed intake moments.

To exposure verification

DEV focuses on the timestamped delivery and receipt of medication as a new input for clinical interpretation.

To adherence intelligence

Massyst aims to transform verified adherence signals into stronger evidence, smarter trial operations and better decisions.

The concept

Understanding not only what was prescribed, but what was actually delivered and received.

Digital Exposure Verification does not replace clinical endpoints, medical judgement or trial protocols. It strengthens the data foundation by making one of the most important variables less invisible.

Because if adherence influences outcomes, should exposure still be an assumption?

For whom

Built for healthcare innovators, pharmaceutical companies, CROs and research organizations.

The paper is intended as a strategic discussion document for organizations exploring the next step in adherence monitoring, decentralized trials, real-world evidence and medication exposure data.

Pharma sponsors

Explore how verified exposure data can improve trial interpretation and post-market evidence.

CROs

Differentiate with a pragmatic adherence-data layer that can support protocol execution and data quality.

Healthcare innovators

Connect medication support in daily life with the future of clinical research infrastructure.

HLTH Europe 2026

Meet Massyst at HLTH Europe 2026

We will introduce Digital Exposure Verification at HLTH Europe 2026 and invite clinical research leaders, CROs and healthcare innovators to join the discussion.

Request the discussion paper